New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

Related Keywords

Redhill ,North Somerset ,United Kingdom ,Michael Chan ,Reza Fathi ,Emily Henderson ,Us National Institute Of Health ,Centre For Immunology ,University Of Hong Kong ,School Of Public Health ,Redhill Biopharma Ltd ,Hill Biopharma ,Hong Kong ,Public Health ,Principal Investigator ,Hazard Ratio ,Orphan Drug ,Covid 19 ,N Vitro ,Micron ,Anti Inflammatory ,Iopharmaceutical ,Dancer ,Fell ,Cholangiocarcinoma ,Constipation ,Diarrhea ,Drugs ,Efficacy ,Nex Vivo ,Ibrosis ,Mmunology ,Infectious Diseases ,Influenza ,Manufacturing ,Ortality ,Opioid Induced Constipation ,Pneumonia ,Reclinical ,Prostate ,Prostate Cancer ,Protein ,Research ,Espiratory ,Na ,Cars ,Ars Cov 2 ,Spike Protein ,Virus ,